References
- Balandin Moreno B, Fernandez Simon I, Pintado Garcia V, Sanchez Romero I, Isidoro Fernandez B, Romera Ortega MA, et al. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients. Scand J Infect Dis 2014;46:175–80.
- Vardakas KZ, Matthaiou DK, Falagas ME, Antypa E, Koteli A, Antoniadou E. Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. J Infect 2014 Nov 15 (Epub ahead of print).
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–81.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial testing: twentieth informational supplement, CLSI document M100-S20.CLSI; 2010.
- FDA. Tygacil (Tigecycline) for injection; 2009. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021821s016lbl.pdf
- Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents 2014;44:1–7.
- Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013;57:1756–62.
- Sbrana F, Malacarne P, Viaggi B, Costanzo S, Leonetti P, Leonildi A, et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 2013;56:697–700.
- Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014; 58:654–63.